Albinterferon Alfa-2B Completed Phase 1 Trials for Human Immunodeficiency Virus (HIV) Infections / Hepatitis C Virus (HCV) Infection Treatment

Indications	Status	Purpose	Phase
DBCOND0035016 (Human Immunodeficiency Virus (HIV) Infections) DBCOND0052122 (Hepatitis C Virus (HCV) Infection)	Completed	Treatment	1

clinicaltrials.gov Identifier	Title	Drugs
NCT00489385	An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals	Albinterferon Alfa-2B (DB05396) Ribavirin (DB00811)